I am a
Home I AM A Search Login

Papers of the Week


Papers: 8 Feb 2020 - 14 Feb 2020


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Itch


2020 Feb 06


BMJ Open


10


2

Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.

Authors

Vincenzi B, Trower M, Duggal A, Guglielmini P, Harris P, Jackson D, Lacouture ME, Ratti E, Tonini G, Wood A, Ständer S
BMJ Open. 2020 Feb 06; 10(2):e030114.
PMID: 32034016.

Abstract

To evaluate the efficacy of orvepitant (10 or 30 mg given once daily, orally for 4 weeks), a neurokinin-1 receptor antagonist, compared with placebo in reducing the intensity of epidermal growth factor receptor inhibitor (EGFRI)-induced intense pruritus.